Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Matilde Lleonart Pajarin LinkedIn Twitter Orcid Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Proyectos Nuevas terapias aplicables a cánceres mamarios de naturaleza agresiva y metastática en base a aniquilar la población de células madre de cáncer. IP: Matilde Lleonart Pajarin Colaboradores: Irene Braña Garcia, Margarita Alberola Ferranti, Sergio Benavente Norza, Carmela Iglesias i Felip, Josep Castellví Vives, Maria Alsina Maqueda Entidad financiadora: Instituto de Salud Carlos III Financiación: 195415 Referencia: PI15/01262 Duración: 01/01/2016 - 30/11/2020 RedOx status of cancer stem cells and their resistance to chemo- and radio-therapy IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: EUROPEAN COMMISSION Financiación: 40986 Referencia: INCOMED - FELLOW 6 Duración: 08/06/2016 - 28/02/2018 RNA binding proteins : Future markers for cancer progression IP: Matilde Lleonart Pajarin Colaboradores: - Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 197196 Referencia: PHD4MD/LLEONART/2015 Duración: 08/07/2015 - 08/07/2018 Oncologia i Patologia Molecular IP: Matilde Lleonart Pajarin Colaboradores: Juan Lorente Guerrero, Margarita Alberola Ferranti, Oncologia i Patologia Molecular, Sergio Benavente Norza Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: Referencia: 2014 SGR 1617 Duración: 01/01/2014 - 31/12/2016 Paginación Primera página « Página anterior ‹ … Página 3 Página 4 Página actual 5 Página 6 Página 7 … Siguiente página › Última página »
